Bispecific antibodies and novel immune cell targets for immuno-oncology

ABL Bio’s immuno-oncology programs are addressing the limitations of current checkpoint inhibitors by developing bispecific antibodies and the next generation of checkpoint inhibitors.

Like Comment
Page of
Go to the profile of ABL Bio


ABL Bio is biotech research company focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. 1. Lead Molecule (ABL001): Bispecific antibody targeting VEGF and Dll4 (Phase 1, Q4, 2017) 2. ADC (Antibody Drug Conjugate) projects 3. T cell engaging Bispecific antibody 4. Immunooncology MoAb 5. Immunooncology Bispecific antibody 6. Synuclein targeting antibody with BBB-Crossing Trojan Horse Bispecific Antibody

No comments yet.